| Ytd | 1.02% | |
| 1y | 14.62% |
| Open | 29.73 | Prev Close | 29.85 | Low | 29.50 | High | 31.20 | Mkt Cap | 1.47B |
| Vol | 247.91K | Avg Vol | 358.42K | EPS | -3.12 | P/E | N/A | Forward P/E | -6.03 |
| Beta | 1.22 | Short Ratio | 8.00 | Inst. Own | 109.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 42.67 | 200-d Avg | 35.81 | 1yr Est | 63.04 |
RAPP News
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a B
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the a
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains
Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wi
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the
Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy ra
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the ana
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweig
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,
